Inspire Medical Stock Price, News & Analysis

Inspire Medical Systems (NYSE: INSP) will announce its financial results for Q2 2022 on August 2, after market hours. A conference call is scheduled for 5:00 p.m. ET to discuss these results and recent business developments. The call can be accessed through a registration link, and a simultaneous webcast will be available on Inspire's Investor Relations page. Inspire specializes in innovative, minimally invasive solutions for obstructive sleep apnea, notably its FDA-approved Inspire therapy, which offers treatment for moderate to severe cases.

Inspire Medical Systems (NYSE: INSP) will present at the Goldman Sachs 43rd Annual Global Healthcare Conference on June 14, 2022, at 7:00 p.m. Eastern Time. The event will take place at the Terranea Resort in Rancho Palos Verdes, CA, with a live webcast accessible at this link. A replay will be available for two weeks on Inspire's Investor website. The company specializes in innovative, minimally invasive treatments for obstructive sleep apnea, including the FDA-approved Inspire therapy, the first neurostimulation technology for this condition.

Inspire Medical Systems announced its participation in the Goldman Sachs 43rd Annual Global Healthcare Conference on June 14, 2022, at 1:00 p.m. Eastern Time. The presentation will focus on Inspire's innovative solutions for obstructive sleep apnea, including its proprietary FDA-approved neurostimulation therapy. Attendees can access the live webcast and a replay of the event, which will be available for two weeks afterwards on Inspire's Investor website.

Inspire Medical Systems is showcasing its innovations at the SLEEP 2022 conference from June 4-8, highlighting the Inspire SleepSync™ digital health platform enabled by a new Bluetooth® remote. The platform now encompasses over 2.5 million nights of sleep data. The company will host an educational symposium on optimizing patient outcomes with Inspire therapy and participate in key scientific sessions discussing upper airway stimulation therapy. Inspire aims to demonstrate its commitment to advancing sleep apnea treatment with interactive physician discussions.

Inspire Medical Systems (NYSE: INSP) announced its management team will present at the UBS Global Healthcare Conference on May 25, 2022, at 1:15 p.m. ET in New York. The presentation will focus on Inspire's innovative, minimally invasive solutions for obstructive sleep apnea, including its FDA-approved neurostimulation technology, Inspire therapy. A live webcast will be available for those unable to attend in person, with a replay accessible for two weeks post-event on Inspire’s investor website.

Inspire Medical Systems (NYSE: INSP) reported a remarkable 72% revenue growth in Q1 2022, reaching $69.4 million, compared to $40.4 million in Q1 2021. The U.S. revenue surged by 76% to $66.4 million. The company's gross margin improved to 85.6%, up from 85.2%. Inspire activated 74 new medical centers, totaling 733 centers, and expanded to 17 new sales territories. The company raised its full-year revenue guidance to $336 million to $344 million, from $318 million to $326 million, anticipating continued positive trends.

Inspire Medical Systems (NYSE: INSP) has announced a $10 million investment in EnsoData to improve sleep lab capacity and efficiency through its AI-driven analysis platform, EnsoSleep, which is already in use at over 500 sleep centers. Additionally, Inspire has provided seed funding to Ognomy, a platform that enhances access to sleep apnea care by facilitating remote diagnosis and treatment. These investments aim to bolster Inspire's digital health strategy, addressing the challenges faced by over 20 million Americans with obstructive sleep apnea.

Inspire Medical Systems, a leader in medical technology, announced that its management team will present at the BofA Securities 2022 Healthcare Conference on May 11, 2022, at 10:40 a.m. Pacific Time. The event will take place at the Encore Hotel in Las Vegas, Nevada and will feature a live webcast accessible through their website. Inspire specializes in innovative solutions for obstructive sleep apnea and offers the only FDA-approved neurostimulation therapy for this condition. A recorded version of the presentation will be available for two weeks post-event.

Inspire Medical Systems, Inc. (NYSE: INSP) will release its first-quarter 2022 financial results on May 3, after market close. Management will host a conference call at 5:00 p.m. ET to discuss these results and recent developments. Inspire specializes in innovative, minimally invasive solutions for obstructive sleep apnea, showcasing its FDA-approved neurostimulation technology as a leading treatment option. For further details, visit Inspire's website.